Replicor Inc在美国肝脏研究协会2020年数字会议上宣布接受四项

StephenW

MONTREAL, November 2nd, 2020 – Replicor Inc., a privately held biopharmaceutical company targeting functional cure for patients with chronic hepatitis B and D infection, announced the acceptance of four presentations at the 2020 digital meeting of the American Association for the Study of the Liver (AASLD / TLMdX) being held from November 13-16, 2020.

These presentations include the following advances:

Identification of the host HSP40 chaperone DNAJB12 as the target for NAPs in the selective inhibition of subviral particle (SVP) assembly and secretion (Poster LP42).

Well tolerated compassionate use of TDF and REP 2165-Mg in a cirrhotic individual with HBV / HDV coinfection, achieving simultaneous clearance of HDV RNA and HBsAg and HBsAg seroconversion (Poster 0827).

In collaboration with Abbott Diagnostics, analysis of HBsAg isoforms in the REP 301 and REP 401 studies providing evidence for the selective targeting of SVP by REP 2139 in humans (Poster 0819).

Demonstration of the inhibition of HBsAg secretion by REP 2139 in a novel cell line expressing only HBsAg and HBx (Poster 0818).

Replicor’s CSO, Dr. Andrew Vaillant commented, “The identification of DNAJB12 as the host NAP target in HBV infection is an important step in understanding the selectivity of the NAP effect for SVP.  With the confirmation of the NAP effect in humans via HBsAg isoform analysis and the safe and effective use of NAPs in a cirrhotic patient, these presentations provide important advances in the understanding of the clinical effects of NAPs and expanding their use in all patients with HBV  infection.”

Replicor’s presentations from TLMdX will become available on the company’s website following the meeting at www.replicor.com/science/conference-presentations.  For further information about the 2020 AASLD meeting (TLMdX), please see https://tlmdx.aasld.org/.

StephenW

蒙特利尔，2020年11月2日– Replicor Inc.是一家私有生物制药公司，致力于为慢性B和D型肝炎感染患者提供功能性治疗，该公司在美国肝脏研究协会2020年数字会议上宣布接受四项演讲（AASLD / TLMdX）将于2020年11月13日至16日举行。

这些演示包括以下进展：

鉴定宿主HSP40伴侣DNAJB12作为NAP的靶点，以选择性抑制亚病毒颗粒（SVP）的组装和分泌（海报LP42）。

在肝炎合并HBV / HDV感染的个体中，对TDF和REP 2165-Mg的耐受性良好，可以同时清除HDV RNA和HBsAg和HBsAg血清转化（海报0827）。

与雅培诊断公司合作，对REP 301和REP 401研究中的HBsAg亚型进行分析，为REP 2139在人中选择性靶向SVP提供了证据（海报0819）。

演示REP 2139在仅表达HBsAg和HBx的新型细胞系中对HBsAg分泌的抑制作用（海报0818）。

复制者的CSO Andrew Vaillant博士评论说：“鉴定DNAJB12作为HBV感染的宿主NAP目标，是理解NAP对SVP的选择性的重要一步。通过对HBsAg亚型的分析证实了NAP对人体的作用以及在肝硬化患者中安全有效地使用NAP，这些介绍为理解NAP的临床效果以及扩大其在所有HBV感染患者中的应用提供了重要的进展。 。”

会议结束后，来自TLMdX的Replicor演示文稿将在该公司的网站上发布，网址为www.replicor.com/science/conference-presentations。有关2020 AASLD会议（TLMdX）的更多信息，请参阅https://tlmdx.aasld.org/。

乙肝人1949

这个公司，哎，己不知用哪个成语表扬它。不过，换个角度，永不言弃，精神可嘉

齐欢畅